Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition

November 26, 2024
, 6:57 pm

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

Roche is acquiring Poseida Therapeutics, a biotech developing allogeneic cell therapies for cancers and immunological indications. The two companies have been partners in hematological malignancies since 2022.

The post Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition appeared first on MedCity News.

Leave a Replay

Healthcare’s Next Frontier: Building a Fully Connected Experience

10 Imperatives of a Medication Intelligence System to Streamline the Pharmacy Lifecycle

4 Announcements GE HealthCare Made at RSNA 2024

Sign up for our Newsletter

HealthGility provides healthcare organizations with a solution for patient protected health information disclosure and confidentiality that reduces workloads and ensures the safe and secure sharing of sensitive data between different providers.

Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition

Leave a Replay

Related Posts

Healthcare’s Next Frontier: Building a Fully Connected Experience

10 Imperatives of a Medication Intelligence System to Streamline the Pharmacy Lifecycle

4 Announcements GE HealthCare Made at RSNA 2024

Follow Us

Sign up for our Newsletter

Our Company

Resources

Connect

© All rights reserved

Contact Us